The drug binding site of human alpha1-acid glycoprotein: insight from induced circular dichroism and electronic absorption spectra.

Human alpha(1)-acid glycoprotein (AGP) is an important drug binding plasma protein which affects pharmacokinetical properties of various therapeutic agents. For the first time, interpretation of the induced circular dichroism (ICD) spectra of drug-AGP complexes is presented yielding valuable information on the protein binding environment. ICD spectra were obtained by novel ligands of which AGP induced optical activity have never been reported (primaquine, mefloquine, propranolol, terazosin, carbamazepine, rhodamine B) and by re-investigation of ICD spectra of protein-bound drugs published earlier (chlorpromazine, dipyridamole, prazosin). Spectroscopic features of the ICD and absorption bands of drugs combined with native AGP indicated chiral non-degenerate exciton coupling between the guest chromophore and the indole ring of an adjacent tryptophan (Trp) residue. Results of additional CD experiments performed by using recombinant AGP mutants showed no changes in the ligand binding ability of W122A in sharp contrast with the W25A which was unable to induce extrinsic CD signal with either ligand. Thus, these findings unequivocally prove that, likely via pi-pi stacking mechanism, Trp25 is essentially involved in the AGP binding of drugs studied here as well as of related compounds. Survey of the AGP binding data published in the literature support this conclusion. Our results provide a fast and efficient spectroscopic tool to determine the inclusion of ligand molecules into the beta-barrel cavity of AGP where the conserved Trp25 is located and might be useful in ligand-binding studies of other lipocalin proteins.

[1]  Narasimha Sreerama,et al.  Computation and Analysis of Protein Circular Dichroism Spectra , 2004, Numerical Computer Methods, Part D.

[2]  Sato,et al.  Characterization of the Chromophore Orientation of Rhodamine B Amphiphiles in Langmuir-Blodgett Monolayers. , 2001, Journal of colloid and interface science.

[3]  Y. Saito,et al.  Calorimetry studies of chlorpromazine hydrochloride in solution , 2000 .

[4]  M. Tabak,et al.  SYNTHESIS, CHARACTERIZATION AND INTERACTION WITH IONIC MICELLES OF TETRAACETYLATED DIPYRIDAMOLE , 1995 .

[5]  P. McNamara,et al.  Autacoid binding to serum proteins. Interaction of platelet activating factor (PAF) with human serum alpha-1-acid glycoprotein (AAG). , 1986, Biochemical pharmacology.

[6]  K. Nakanishi,et al.  Quantitative definition of exciton chirality and the distant effect in the exciton chirality method , 1975 .

[7]  B Testa,et al.  Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. , 1998, Molecular pharmacology.

[8]  R. Sonders Pharmacokinetics of terazosin. , 1986, The American journal of medicine.

[9]  W. Schaper Dipyridamole, an Underestimated Vascular Protective Drug , 2005, Cardiovascular drugs and therapy.

[10]  M. Otagiri,et al.  Characterization of Drug Binding Sites on α1-Acid Glycoprotein , 1990 .

[11]  L. Cubeddu,et al.  Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. , 1986, Journal of pharmaceutical sciences.

[12]  Yoshihisa Inoue,et al.  The pH dependence of the anisotropy factors of essential amino acids , 2002 .

[13]  U. Westphal,et al.  Steroid-protein interactions. XXXIV. Chemical modification of alpha1-acid glycoprotein for characterization of the progesterone binding site. , 1976, Biochimica et biophysica acta.

[14]  Z. Bikádi,et al.  Induced chirality upon crocetin binding to human serum albumin: origin and nature , 2001 .

[15]  I. Polyakova,et al.  Crystal structure of the 1:2.5 molecular complex of the internal salt of [6-(diethylamino)-9-[2-(fluorosulfonyl)-4-sulfophenyl]-3h-xanthen-3-ylidene]diethylammonium hydroxide with ethanol , 1985 .

[16]  K. Hanada,et al.  Enantioselective Binding of Propranolol, Disopyramide, and Verapamil to Human α1‐Acid Glycoprotein , 2000 .

[17]  W. Müller,et al.  Characterization of a common binding site for basic drugs on human α2-acid glycoprotein (orosomucoid) , 1983, Naunyn-Schmiedeberg's Archives of Pharmacology.

[18]  J. Barré,et al.  Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycop , 1996, Pharmacogenetics.

[19]  T. Maruyama,et al.  Further characterization of reversal of signs of induced cotton effects of dicumarol derivatives-alpha 1-acid glycoprotein systems by protriptyline. , 1992, Biochemical pharmacology.

[20]  F. Zsila,et al.  Circular dichroism and absorption spectroscopic data reveal binding of the natural cis-carotenoid bixin to human α1-acid glycoprotein , 2005 .

[21]  H. Matsunaga,et al.  Multiple ligand-binding properties of the lipocalin member chicken alpha1-acid glycoprotein studied by circular dichroism and electronic absorption spectroscopy: the essential role of the conserved tryptophan residue. , 2006, Biochimica et biophysica acta.

[22]  Z H Israili,et al.  HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.

[23]  R. Farinotti,et al.  Enantioselective chromatography of the antimalarial agents chloroquine, mefloquine, and enpiroline on a α1-acid glycoprotein chiral stationary phase : evidence for a multiple-site chiral recognition mechanism , 1992 .

[24]  J. Albani Tertiary structure of human alpha1-acid glycoprotein (orosomucoid). Straightforward fluorescence experiments revealing the presence of a binding pocket. , 2004, Carbohydrate research.

[25]  T. Imai,et al.  A comparative study of the interaction of warfarin with human α1‐acid glycoprotein and human albumin , 1987, The Journal of pharmacy and pharmacology.

[26]  A. Skerra,et al.  Comparative ligand-binding analysis of ten human lipocalins. , 2006, Biochimica et biophysica acta.

[27]  H. Halsall,et al.  Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents. , 1985, The Biochemical journal.

[28]  M. Sugawara,et al.  Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. , 2003, British journal of clinical pharmacology.

[29]  M. Otagiri,et al.  A molecular functional study on the interactions of drugs with plasma proteins. , 2005, Drug metabolism and pharmacokinetics.

[30]  L. H. Chen,et al.  Topography of human plasma alpha1-acid glycoprotein. , 1976, Biochemistry.

[31]  F. Brunner,et al.  Prazosin binding to human α1‐acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid , 1985, The Journal of pharmacy and pharmacology.

[32]  K. Schmid Preparation and Properties of Serum and Plasma Proteins. XXIX. Separation from Human Plasma of Polysaccharides, Peptides and Proteins of Low Molecular Weight. Crystallization of an Acid Glycoprotein1a,b,c , 1953 .

[33]  H. Halsall,et al.  The lipocalin model for human orosomucoid: Support from the chromatography of orosomucoid-monoclonal antibody complexes , 1994 .

[34]  D. Raines,et al.  Development of a novel probe for measuring drug binding to the F1*S variant of human alpha 1-acid glycoprotein. , 2001, Journal of pharmaceutical sciences.

[35]  G. Bandoli,et al.  X-ray crystallographic characterization of 10,11-dihydro-5H-dibenz[b, f ]azepine-5-carboxamide , 1992 .

[36]  Rüdiger Ettrich,et al.  Structure of human α1-acid glycoprotein and its high-affinity binding site , 2003 .

[37]  T. Burghardt,et al.  Conformation of xanthene dyes in the sulfhydryl 1 binding site of myosin. 2. , 1995, Biochemistry.

[38]  Ulrich Westphal,et al.  Steroid-Protein Interactions , 1971, Monographs on Endocrinology.

[39]  Z. Bikádi,et al.  Induced circular dichroism spectra reveal binding of the antiinflammatory curcumin to human alpha1-acid glycoprotein. , 2004, Bioorganic & medicinal chemistry.

[40]  S. Mason,et al.  Linear and circular dichroism studies of DNA-monoaminoacridine complexes , 1971 .

[41]  M. Tabak,et al.  Electronic absorption and fluorescence spectroscopic studies of dipyridamole: Effects of solution composition , 1992 .

[42]  T. Hazlett,et al.  Optical spectroscopy in studies of antibody-hapten interactions. , 2000, Methods.

[43]  E. Zola,et al.  Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein. , 1984, British journal of clinical pharmacology.

[44]  T. Imai,et al.  Drug Binding to α1-Acid Glycoprotein Studied by Circular Dichroism , 2004, Pharmaceutical Research.

[45]  M. Otagiri,et al.  Investigation of the Interaction Mode of Phenothiazine Neuroleptics with α1‐Acid Glycoprotein , 1992 .

[46]  E. Nanba,et al.  Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S , 1997, Human Genetics.

[47]  J. Albani Progesterone binding to the tryptophan residues of human α1-acid glycoprotein , 2006 .

[48]  H. Frischer,et al.  Distribution of primaquine in human blood: drug-binding to alpha 1-glycoprotein. , 1990, The Journal of laboratory and clinical medicine.

[49]  G. Brett,et al.  Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands. , 2000, Pharmacological reviews.

[50]  J. D. Bell,et al.  The crystal structure of phenothiazine , 1968 .

[51]  N. Yamaotsu,et al.  Use of Photoaffinity Labeling and Site-directed Mutagenesis for Identification of the Key Residue Responsible for Extraordinarily High Affinity Binding of UCN-01 in Human α1-Acid Glycoprotein* , 2005, Journal of Biological Chemistry.

[52]  J. Kremer,et al.  Drug binding to human alpha-1-acid glycoprotein in health and disease. , 1988, Pharmacological reviews.

[53]  F. Zsila,et al.  Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. , 2006, Biochimica et biophysica acta.

[54]  U. Wollert,et al.  Binding of several phenothiazine neuroleptics to a common binding site of alpha 1-acid glycoprotein, orosomucoid. , 1983, Journal of pharmaceutical sciences.

[55]  J. Schley Inhibitory effect of phenothiazines on the binding of [3H]perazine to α1‐acid glycoprotein , 1987 .

[56]  Z. Bikádi,et al.  Specific ligand binding on genetic variants of human alpha1-acid glycoprotein studied by circular dichroism spectroscopy. , 2004, Biochemical pharmacology.